Resistance to newer beta-lactam/inhibitor combinations

9:30 AM • 1331 • <em>In vitro</em> synergistic activity of ceftazidime/avibactam in combination with five other antibiotics against carbapenemase-producing <em>Klebsiella pneumoniae</em> > K. Klaus BIEHLER (Freiburg) 9:35 AM • 1885 • German multi-centre study on standardised MIC determination of ceftazidime-avibactam against extensively drug-resistant clinical <em>Pseudomonas aeruginosa</em> isolates from 2017-2019 > R. Raphael STAUF (Nuremberg) 9:40 AM • 1926 • Mechanisms leading to high-level resistance to ceftolozane/tazobactam and ceftazidime/avibactam in multidrug-resistant <em>Pseudomonas aeruginosa </em>isolates from northern Spain > J. Jorge ARCA-SUÁREZ (A Coruña) 9:45 AM • 2337 • <em>In vitro</em> activity of imipenem/relebactam against <em>Klebsiella pneumoniae</em> and <em>Pseudomonas aeruginosa</em> isolates from patients with respiratory tract infections in the Asia/Pacific region: SMART 2017-2019 > K. Krystyna KAZMIERCZAK (Schaumburg) 9:50 AM • 2446 • Outbreak of a cefiderocol and ceftazidime/avibactam-resistant <i>bla</i>KPC-62- and <i>bla</i>CTX-M-15-producing<em> Klebsiella pneumoniae</em> in a university hospital in Madrid, Spain > J. Juan Antonio DEL CASTILLO POLO (Madrid) 9:55 AM • 2691 • Increasing rate of ceftazidime-avibactam resistance among patients with carbapenem-resistant <em>Pseudomonas aeruginosa</em> infections: a real-life report from an intensive care unit in Italy > A. Arcangelo SCHIATTARELLA (Rome) 10:00 AM • 3164 • <em>In vitro</em> activity of meropenem/vaborbactam and of ceftazidime/avibactam against carbapenemase-producing <em>Enterobacteriaceae</em> isolated in Western Normandy, France during 2015 to 2020 > L. Laura BETTANE (Caen) 10:05 AM • 652 • <em>In vitro</em> activities of ceftazidime-avibactam and comparator agents against <em>Pseudomonas aeruginosa</em> from Europe stratified by region, ATLAS global surveillance programme, 2018-2019 > K. Krystyna KAZMIERCZAK (Schaumburg) 10:10 AM • 654 • <em>In vitro</em> activities of ceftazidime-avibactam and comparator agents against Enterobacterales and <em>Pseudomonas aeruginosa</em> from Turkey, collected through the ATLAS global surveillance programme, 2013-2019 > M. Meredith HACKEL (Schaumburg) 10:15 AM • 901 • Ceftazidime-avibactam antimicrobial activity against Gram-negative bacteria isolated from intensive care unit (ICU) patients in the United States Medical Centres (2017-2019) > H. Helio S. SADER (North Liberty) 10:20 AM • INT73 • Q&A/Discussion